Mirati’s adagrasib scores encouraging results in KRAS-mutated lung cancer
Adagrasib is an investigational oral small-molecule inhibitor of KRAS G12C
Read More
Tag: KRAS mutation
Promising early results for new ovarian cancer drug combo
Drug combination could offer a new option for treatment-resistant advanced ovarian cancer
Read More
CRUK scientists develop drug that targets KRAS pathways
KRAS mutations are found in several hard-to-treat cancers
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
